Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Astellas Pharma Inc

Healthcare US ALPMY

13.29USD
-0.25(1.85%)

Last update at 2026-06-05T19:28:00Z

Day Range

13.2913.49
LowHigh

52 Week Range

8.6116.88
LowHigh

Fundamentals

  • Previous Close 13.54
  • Market Cap28310.16M
  • Volume7705
  • P/E Ratio35.59
  • Dividend Yield3.25%
  • EBITDA608503.99M
  • Revenue TTM2060613.98M
  • Revenue Per Share TTM1150.64
  • Gross Profit TTM 1668997.05M
  • Diluted EPS TTM0.44

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Income before tax 31237.00M 24969.00M 132361.00M 156886.00M 145324.00M
Minority interest - - - - -
Net income 50747.00M 17045.00M 98714.00M 124086.00M 120589.00M
Selling general administrative 843032.00M 740110.00M 630272.00M 548840.00M 504316.00M
Selling and marketing expenses - - - - -
Gross profit 1563117.00M 1311187.00M 1230266.00M 1043154.00M 1003465.00M
Reconciled depreciation 199132.00M 157840.00M 105738.00M 79684.00M 72652.00M
Ebit 48914.00M 36974.00M 140928.00M 137601.00M 147659.00M
Ebitda 248046.00M 194814.00M 246666.00M 217285.00M 220311.00M
Depreciation and amortization 199132.00M 157840.00M 105738.00M 79684.00M 72652.00M
Non operating income net other - - - - -
Operating income 41039.00M 25518.00M 133029.00M 155686.00M 136051.00M
Other operating expenses 1871284.00M 1578154.00M 1387062.00M 1165200.00M 1113955.00M
Interest expense 17677.00M 12005.00M 8779.00M 4949.00M 2335.00M
Tax provision -19510.00000M 7924.00M 33647.00M 32800.00M 24734.00M
Interest income 7874.00M 11455.00M 8110.00M 6149.00M 11608.00M
Net interest income -9803.00000M -550.00000M -669.00000M 1200.00M 9273.00M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -19510.00000M 7924.00M 33647.00M 32800.00M 24734.00M
Total revenue 1912323.00M 1603672.00M 1518619.00M 1296163.00M 1249528.00M
Total operating expenses 1522078.00M 1285669.00M 1098709.00M 912191.00M 867892.00M
Cost of revenue 349206.00M 292485.00M 288353.00M 253009.00M 246063.00M
Total other income expense net -9802.00000M -549.00000M -99291.00000M -61259.00000M -105609.00000M
Discontinued operations - - - - -
Net income from continuing ops 50747.00M 17045.00M 98714.00M 124086.00M 120590.00M
Net income applicable to common shares - - - 124086.00M 120589.00M
Preferred stock and other adjustments - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 3339544.00M 3569603.00M 2456518.00M 2332395.00M 2273628.00M
Intangible assets 1123714.00M 1453824.00M 562496.00M 623431.00M 651427.00M
Earning assets - - - - -
Other current assets 53250.00M 46536.00M 32428.00M 28998.00M 19658.00M
Total liab 1826289.00M 1973615.00M 948564.00M 872087.00M 887513.00M
Total stockholder equity 1513255.00M 1595988.00M 1507954.00M 1460308.00M 1386115.00M
Deferred long term liab - - - - -
Other current liab 572688.00M 589739.00M 585798.00M 556672.00M 467595.00M
Common stock 103001.00M 103001.00M 103001.00M 103001.00M 103001.00M
Capital stock 103001.00M 103001.00M 103001.00M 103001.00M 103001.00M
Retained earnings 740939.00M 809400.00M 908158.00M 944261.00M 953289.00M
Other liab - - 106852.00M 128986.00M 152578.00M
Good will 415207.00M 418694.00M 328411.00M 303030.00M 284011.00M
Other assets - - 84170.00M 72330.00M 54175.00M
Cash 188372.00M 335687.00M 376840.00M 315986.00M 326128.00M
Cash and equivalents - - - - -
Total current liabilities 1061610.00M 1285725.00M 726034.00M 687411.00M 592372.00M
Current deferred revenue - 38515.00M - - -
Net debt 643054.00M 584329.00M -376840.00000M -315986.00000M -326128.00000M
Short term debt 266533.00M 472278.00M - - -
Short long term debt 266533.00M 472278.00M - - -
Short long term debt total 831426.00M 920016.00M - - -
Other stockholder equity 669315.00M 683587.00M -1011159.00000M -1047262.00000M -1056290.00000M
Property plant equipment - - 286459.00M 269044.00M 264623.00M
Total current assets 1201349.00M 1194730.00M 1049954.00M 923354.00M 872588.00M
Long term investments - - - - -
Net tangible assets - - - 533847.00M 450677.00M
Short term investments 29941.00M 28784.00M 19784.00M 21297.00M 5560.00M
Net receivables 632525.00M 534985.00M 446516.00M 404001.00M 357162.00M
Long term debt 564893.00M 447738.00M - - -
Inventory 297261.00M 248738.00M 174386.00M 153072.00M 164080.00M
Accounts payable 187840.00M 185193.00M 140236.00M 130739.00M 124777.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 533301.00M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.00M 45595.00M 1.00M -1.00000M -1.00000M
Deferred long term asset charges - - - - -
Non current assets total 2138195.00M 2374873.00M 1406564.00M 1409041.00M 1401040.00M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Investments -89419.00000M -845802.00000M -84500.00000M -62413.00000M -81894.00000M
Change to liabilities - - 0.00000M -10101.00000M -51569.00000M
Total cashflows from investing activities -89419.00000M -845802.00000M - -62413.00000M -81894.00000M
Net borrowings -88522.00000M 771233.00M -15000.00000M -60000.00000M -126000.00000M
Total cash from financing activities -261367.00000M 614060.00M -195623.00000M -216298.00000M -229479.00000M
Change to operating activities - - - -16639.00000M 47389.00M
Net income 31237.00M 17045.00M 132361.00M 156886.00M 145324.00M
Change in cash -147315.00000M -41153.00000M 60854.00M -10142.00000M 7737.00M
Begin period cash flow 335687.00M 376840.00M 315986.00M 326128.00M 318391.00M
End period cash flow 188372.00M 335687.00M 376840.00M 315986.00M 326128.00M
Total cash from operating activities 194512.00M 172475.00M 327767.00M 257444.00M 306843.00M
Issuance of capital stock - - - - -
Depreciation 199132.00M 157840.00M 105738.00M 79684.00M 72652.00M
Other cashflows from investing activities -65336.00000M -22772.00000M - -10017.00000M 3632.00M
Dividends paid 128993.00M 116653.00M -100355.00000M -85236.00000M -76157.00000M
Change to inventory -50225.00000M -60036.00000M -7086.00000M 24058.00M -2318.00000M
Change to account receivables -104735.00000M -55948.00000M -4849.00000M -8001.00000M 22161.00M
Sale purchase of stock -6960.00000M -10735.00000M -60556.00000M -50717.00000M -9163.00000M
Other cashflows from financing activities -36892.00000M -29785.00000M -3217.00000M -2530.00000M -2268.00000M
Change to netincome - - 15688.00M 31557.00M 73204.00M
Capital expenditures 57330.00M 82497.00M 88541.00M 76448.00M 77441.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -166369.00000M -86518.00000M -24209.00000M 5956.00M -31726.00000M
Stock based compensation - - - - -
Other non cash items 130512.00M 84108.00M 113877.00M 14918.00M 120593.00M
Free cash flow 137182.00M 89978.00M 239226.00M 180996.00M 229402.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ALPMY
Astellas Pharma Inc		 -0.25 1.85% 13.29 35.59 12.82 0.01 2.61 2.52 14.54
LLY
Eli Lilly and Company		 6.15 0.55% 1131.42 78.14 31.95 16.34 45.83 16.65 54.36
JNJ
Johnson & Johnson		 4.60 2.02% 232.77 29.17 14.33 3.74 5.18 3.80 15.22
ABBV
AbbVie Inc		 2.29 1.02% 227.23 86.32 14.33 5.89 50.46 7.04 24.44
AZN
AstraZeneca PLC		 4.15 2.28% 185.95 30.69 19.23 5.30 6.45 5.72 17.23

Reports Covered

Stock Research & News

View All

Profile

Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy secondary to age-related macular degeneration; EVRENZO, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It has a research collaboration with xFOREST Therapeutics to develop RNA-targeted therapies and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize an integrated diabetes self-management solution. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.

Astellas Pharma Inc

2-5-1, Nihonbashi-Honcho, Chuo, Japan, 103-8411

Key Executives

Name Title Year Born
Mr. Kenji Yasukawa Ph.D. Pres, CEO & Chairman 1960
Mr. Naoki Okamura BSc Exec. VP, Chief Strategy Officer & Representative Director NA
Minoru Kikuoka CFO & Sr. Managing Exec. Officer NA
Nobue Yasuda Gen. Mang. of Fin. & Accounting Department NA
Mr. Yoshitsugu Shitaka Ph.D. Chief Scientific Officer & Sr. Managing Exec. Officer NA
Ms. Catherine B. Levitt Gen. Counsel NA
Mr. Katsuyoshi Sugita Chief People Officer and Chief Ethics & Compliance Officer NA
Mr. Stig Ogata VP of Corp. Communications NA
Ms. Collette Taylor Sr. VP of HR 1963
Chihiro Yokota Sr. Corp. Exec. and Head of Japan/Asia Devel., Devel. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions